<DOC>
	<DOCNO>NCT00570089</DOCNO>
	<brief_summary>1 . To evaluate impact ranolazine extended-release tablet woman subendocardial ischemia due microvascular endothelial dysfunction myocardial ischemia ( Cardiac Magnetic Resonance ( CMR ) extent , severity . 2 . To evaluate impact ranolazine extended-release tablet woman subendocardial ischemia due microvascular endothelial dysfunction outcome angina ( Seattle Angina Questionnaire ( SAQ ) , WISE angina frequency , Duke Activity Status Inventory ( DASI ) SF-36 ) .</brief_summary>
	<brief_title>Microvascular Coronary Disease In Women : Impact Of Ranolazine</brief_title>
	<detailed_description>Interested woman consider study meet inclusion exclusion criterion include review baseline CMR , ECG blood work ( liver kidney function ) . The baseline CMR must complete within 12 month previous enrollment . Eligible woman angina CMR subendocardial perfusion abnormality , define CMR qualitative perfusion abnormality great equal 10 % report abnormal follow blind review per protocol , consent enrol . The woman complete baseline demographic health history questionnaire , include SAQ , Women 's Ischemic Syndrome Evaluation ( WISE ) angina frequency , DASI SF-36 . This study double-blind , placebo control , cross-over design treatment order ranolazine placebo randomly assign . Note : The participant 's usual medication regimen continue throughout study participation . Following enrollment study , participant randomize treatment # 1 ( either placebo ranolazine ) . Ranolazine dose 500 mg orally twice daily 2 week , assume tolerance , follow 1000 mg orally twice daily additional 2 week . If participant unable increase dose secondary side effect , remain 500 mg twice daily second 2 week interval . The first end treatment CMR ( CMR 1 ) schedule end 4th week treatment , approximately 4 hour morning dose study drug . At visit ( Vis 2 ) , concurrent medication , symptom , adverse event review . Clinical measurement take ( weight , BP , waist hip circumference ) questionnaires complete ( SAQ , WISE angina frequency , DASI SF-36 ) . After first course study treatment , patient undergo two week wash-out study drug continue usual medication regimen . Following washout period , study participant start second cycle study drug treatment ( i.e. , study drug receive treatment 1 ) . At visit 3 , participant undergo baseline 2 measurement include concurrent medication symptom assessment , clinical measurement ( weight , BP , waist hip circumference ) complete baseline 2 questionnaire ( SAQ , WISE angina frequency , DASI SF-36 ) . Study drug treatment # 2 follow escalation study drug dose describe treatment 1 . The final study CMR ( CMR 2 ) schedule end 4th week treatment 2 , approximately 4 hour morning dose study drug . At visit ( Vis 4 ) , concurrent medication , symptom , adverse event review . Clinical measurement take ( weight , blood pressure , waist hip circumference ) questionnaires complete ( SAQ , WISE angina frequency , DASI SF-36 ) . [ See Table 1 listing study procedure visit . ] The two post study drug treatment CMRs perform time day , replicate temperature , fast state , adenosine dose infusion , magnet setting use over-reader . The dose adenosine consistent study CMR test : 140 mcg/kg 5 minute .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>1 . Women sign symptom myocardial ischemia ( chest pain , abnormal stress testing , abnormal noninvasive testing ) absence obstructive coronary artery disease ( epicardial coronary stenosis &lt; 50 % luminal diameter stenosis ) . 2 . Women â‰¥10 % myocardial ischemia CMR perfusion . 1 . Contraindications withhold nitrate , betablockers , calcium channel agent , ACE/ARB agents 48 hour prior test . 2 . Contraindications CMR include AICD , pacemaker , untreatable claustrophobia know angioedema . 3 . Contraindications ranolazine include hepatic insufficiency , prolong QT , renal failure . 4 . Women take drug inhibit CYP3A diltiazem , verapamil , ketoconazole , macrolides HIV protease inhibitor . 5 . Women le 18 year age . 6 . Women drug prolong QT interval Class Ia III antiarrhythmic agent , erythromycin , certain antipsychotic . 7 . Pregnancy breast feed . 8 . Life expectancy le 6 month .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Ranolazine</keyword>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Double blind</keyword>
	<keyword>Placebo control</keyword>
</DOC>